Kubota Toru, Takeshita Akira
Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences.
Nihon Rinsho. 2003 May;61(5):801-6.
Recent large-scale clinical trials have provided credible evidence that angiotensin-converting enzyme inhibitors and beta-blockers can prolong the survival in patients with chronic heart failure. Treatment of asymptomatic left ventricular dysfunction is as important as treatment of symptomatic disease. Addition of aldosterone antagonists to angiotensin-converting enzyme inhibitors and beta-blockers may afford further benefits in patients with severe heart failure. If angiotensin-converting enzyme inhibitors or beta-blockers are not tolerated, angiotensin receptor blockers should be considered as the alternative. The present article will review recent advances in treatment of heart failure based on large-scale clinical trials.
近期的大规模临床试验提供了可信证据,表明血管紧张素转换酶抑制剂和β受体阻滞剂可延长慢性心力衰竭患者的生存期。无症状左心室功能障碍的治疗与有症状疾病的治疗同样重要。在血管紧张素转换酶抑制剂和β受体阻滞剂基础上加用醛固酮拮抗剂可能会给重度心力衰竭患者带来更多益处。如果不能耐受血管紧张素转换酶抑制剂或β受体阻滞剂,应考虑将血管紧张素受体阻滞剂作为替代药物。本文将基于大规模临床试验综述心力衰竭治疗的最新进展。